glp-1 screening kit Human ELISA (BMS2194) At-Home GLP-1 Test

July 17, 2025: EU Clears Ozempic for Heart Conditions, Even Though Reports of Side Effects Are Rising Drug regulators in the European Union have given doctors the all-clear to prescribe Ozempic to treat peripheral artery disease, a type of heart condition

It can also be prescribed off-label for individuals with a BMI of 27 or higher (overweight) who also have weight-related health conditions such as type 2 diabetes, hypertension, or high cholesterol

Q5: Can GLP-1s be used for non-diabetic weight loss

Clinical studies have demonstrated substantial weight loss results with semaglutide GLP-1, particularly when used as part of a structured weight management program

Plus, the powerful thermogenic ingredients kick metabolism into overdrive while t

The primary endpoints were changes in HbA1c and body weight ( 4.2 SURPASS-2 trial comparison of tirzepatide and semaglutide The SURPASS-2 trial, comprising 1,879 patients with type 2 diabetes, compared once-weekly tirzepatide (5 mg, 10 mg, 15 mg) with semaglutide 1 mg over a 40-week period